|Application ||WB, E|
|Calculated MW||21554 Da|
|Antigen Region||1-30 aa|
|Other Names||T-cell receptor gamma-2 chain C region, T-cell receptor gamma chain C region PT-gamma-1/2, TRGC2, TCRGC2|
|Target/Specificity||This TRGC2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human TRGC2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||TRGC2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Membrane; Single-pass membrane protein|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
T cell receptors (TCR) recognize foreign antigens which have been processed as small peptides and bound to major histocompatibility complex (MHC) molecules at the surface of antigen presenting cells (APC). Each T cell receptor is a dimer consisting of one a and one b chain or one d and one g chain. This region represents the germline organization of the T cell receptor beta locus. The beta locus includes V (variable), J (joining), diversity (D), and C (constant) segments. During T cell development, the beta chain is synthesized by a recombination event at the DNA level joining a D segment with a J segment; a V segment is then joined to the D-J gene. The C segment is later joined by splicing at the RNA level. The g/d TCR associates with CD3 and is expressed on a T cell subset found in the thymus, the intestinal epithelium, and the peripheral lymphoid tissues and peritoneum. Most g/d T cells are CD4-/CD8-, some are CD8+. T cells expressing the g/d TCR have been shown to play a role in oral tolerance, tumor-associated tolerance, and autoimmune disease.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.